Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | PLAT | P00750 | 3/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.34 |
| ▸ | CDK9 | P50750 | 4/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.34 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092287 | 0.91 | PLAT (0.37) | NAMPTPLATKDM5BRETKDM5A | |
| SCHEMBL17547814 | 0.90 | PLAT (0.37) | NAMPTPLATCCNT1CDK9KDM5B | |
| SCHEMBL17547816 | 0.87 | KDM5B (0.42) | NAMPTPLATKDM5BADAM10MMP2 | |
| SCHEMBL17547817 | 0.86 | PLAT (0.39) | PLATKDM5BKDM5A | |
| SCHEMBL16092290 | 0.85 | KDM5A (0.34) | PLATKDM5BRETKDM5AJAK1 | |
| SCHEMBL16092288 | 0.82 | PLAT (0.38) | PLATKDM5BRETKDM5A | |
| SCHEMBL17547824 | 0.80 | KDM5B (0.41) | PLATKDM5BKDM5A | |
| SCHEMBL17547843 | 0.78 | PLAT (0.40) | PLATCCNT1CDK9KDM5BKDM5A | |
| SCHEMBL16092399 | 0.78 | TBK1 (0.37) | PLATCDK9KDM5BRETKDM5A | |
| SCHEMBL16092289 | 0.77 | PLAT (0.35) | PLATKDM5BKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | NAMPT 1790/4885PLAT 4107/4885CCNT1 4345/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | NAMPT 1790/4885PLAT 4107/4885CCNT1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.